Geode Capital Management
ZNTL icon

Geode Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Geode Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Buy
1,284,117
+663,081
+107% +$2.65M ﹤0.01% 2802
2026
Q1 		$1.45M Buy
621,036
+31,931
+5% +$82.5K ﹤0.01% 3237
2025
Q4 		$796K Sell
589,105
-117
-0% -$170 ﹤0.01% 3441
2025
Q3 		$890K Sell
589,222
-28,945
-5% -$43.4K ﹤0.01% 3420
2025
Q2 		$717K Sell
618,167
-737,502
-54% -$973K ﹤0.01% 3436
2025
Q1 		$2.16M Buy
1,355,669
+42,705
+3% +$92.1K ﹤0.01% 3006
2024
Q4 		$3.98M Buy
1,312,964
+20,864
+2% +$68.4K ﹤0.01% 2852
2024
Q3 		$4.76M Sell
1,292,100
-42,359
-3% -$154K ﹤0.01% 2784
2024
Q2 		$5.46M Buy
1,334,459
+32,222
+2% +$360K ﹤0.01% 2676
2024
Q1 		$20.5M Buy
1,302,237
+48,500
+4% +$667K ﹤0.01% 1908
2023
Q4 		$19M Buy
1,253,737
+66,900
+6% +$976K ﹤0.01% 1953
2023
Q3 		$23.8M Buy
1,186,837
+119,236
+11% +$3.03M ﹤0.01% 1712
2023
Q2 		$30.1M Buy
1,067,601
+171,676
+19% +$4.12M ﹤0.01% 1581
2023
Q1 		$15.4M Buy
895,925
+38,708
+5% +$784K ﹤0.01% 1972
2022
Q4 		$17.3M Buy
857,217
+21,007
+3% +$452K ﹤0.01% 1867
2022
Q3 		$18.1M Buy
836,210
+54,766
+7% +$1.5M ﹤0.01% 1809
2022
Q2 		$22M Buy
781,444
+115,380
+17% +$3.06M ﹤0.01% 1700
2022
Q1 		$30.7M Buy
666,064
+4,853
+0.7% +$262K ﹤0.01% 1597
2021
Q4 		$55.6M Buy
661,211
+18,557
+3% +$1.44M 0.01% 1228
2021
Q3 		$42.8M Buy
642,654
+198,889
+45% +$11.5M 0.01% 1406
2021
Q2 		$23.6M Buy
443,765
+76,925
+21% +$4.12M ﹤0.01% 1855
2021
Q1 		$15.9M Buy
366,840
+35,051
+11% +$1.51M ﹤0.01% 2023
2020
Q4 		$17.2M Buy
331,789
+150,342
+83% +$6.78M ﹤0.01% 1812
2020
Q3 		$5.93M Buy
181,447
+19,112
+12% +$669K ﹤0.01% 2291
2020
Q2 		$7.79M Buy
+162,335
New +$6.23M ﹤0.01% 2080

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management's ZNTL Position: Q2 2026 in Review

Geode Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 107% in Q2 2026, buying an estimated $2.65M and bringing the position to 1,284,117 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2802.

Geode Capital Management first reported a position in ZNTL in Q2 2020 and has held it in 25 quarters since. The position peaked at $55.6M in Q4 2021. 103 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Geode Capital Management held 1,284,117 shares of Zentalis Pharmaceuticals worth $6.23M as of Q2 2026.
  • Geode Capital Management bought 663,081 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.65M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2802 holding.
  • Geode Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Geode Capital Management's Zentalis Pharmaceuticals position peaked at $55.6M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.